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bstract
In this paper, we utilized dimethylhydrazine (DMH)-induced colorectal cancer (CC) model rats to explore the effects of casein glycomacropeptide
CGMP) on colorectal cancer. Rats with CC were orally administrated with 10, 50, or 100 mg/kg bw d CGMP, or the same volume of phosphate-
uffered saline for 15 weeks. The total numbers of aberrant crypt foci (ACF) and crypts per focus in colon were scored using a light microscope at
ow magnification after the colon was stained with methylene blue solutions. The methylation level of DNA extracted from colon was detected using
ethylation-specific PCR. The expression of p16 and mucin 2 (MUC2) proteins were measured by immunohistochemistry. The results showedhat although ACF were found in rats treated with CGMP, their number was significantly decreased compared to that of model rats. In addition,
ethylation and expression levels of p16 and MUC2 were also inhibited by CGMP, which were more obvious in rats treated with 50 mg/kg bw d
GMP. In conclusion, CGMP has potential application as nutritional therapy for preventing colorectal cancer.
 2013 Beijing Academy of Food Sciences. Production and hosting by Elsevier B.V. All rights reserved.
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.  Introduction
Delfour et al. [1] in 1965 found a sialic acid contain-
ng polypeptide from milk-derived   casein. This polypeptide
ontained two components: one was insoluble sub--casein pro-
uced by chymosin digestion of -casein at Phe (105) and Met
106) residues during cheese production, and the other was the
CA-soluble caseino-macropeptide (CMP). About 30%–50%
MP was present in glycosylated form and named as casein
lycomacropeptide (CGMP). Studies have found that CGMP
as multiple biological activities such as promoting probi-
tics growth [2], regulating immune activity [3] and inhibiting
nfluenza virus [4]. However, whether it plays a role in colorectal
ancer has not been reported at home and abroad.∗ Corresponding author at: College of Biotechnology and Food Science, Tian-
in University of Commerce, East Entrance of Jinba Road, Beichen District,
ianjin 300134, China. Tel.: +86 22 26667631; fax: +86 22 27725382.
E-mail address: chqsen@tjcu.edu.cn (Q. Chen).
eer review under responsibility of Beijing Academy of Food Sciences.
213-4530 © 2013 Beijing Academy of Food Sciences. Production and
osting by Elsevier B.V. All rights reserved.
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In recent years, the incidence of colorectal cancer has risen
o the third place and its mortality rate ranked the second among
alignant tumors. Thus, in-depth studies on the apparent molec-
lar and genetic mechanisms of colorectal tumorigenesis and
evelopment of effective early molecular marker would have
mportant implications for the prevention, diagnosis and treat-
ent of colorectal cancer.
Studies on bioactive peptides are extremely active at home
nd aboard. Jolles [5] isolated a functional peptide from
he degradation products of casein with chrymosin and chy-
otrypsin and found the peptide could stimulate macrophages
nd erythrocytes. Parker et al. [6] isolated two active pep-
ides from casein and found they could inhibit the growth of
umor cells. Belshaw et al. [7] laid the foundation of colorec-
al cancer screening by detecting methylation of 6 genes using
eces as sample and first confirmed the feasibility of detect-
ng fecal DNA methylation for colorectal cancer screening.
uang et al. [8] found that expression of mucin 2 (MUC2)
ight be involved in the tumorigenesis and development of
olorectal cancer, and closely related with its invasion, lymph
ode metastasis and Dukes staging, implicating that MUC2
xpression level may be correlated with the invasiveness of
olorectal cancer. Pang et al. [23] reviewed the effects of
utrients, functional food ingredients and dietary on DNA
ethylation and believed that individual nutrients and func-
ional food ingredients could alter DNA methylation and
xpression, and these epigenetic changes may affect peoples’
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ealth by influencing bodies’ physiological and pathological
rocesses.
In this study, we preliminarily studied the therapeutic effects
f CGMP treatment on DMH induced colorectal cancer in
imethylhydrazine (DMH) induced colorectal cancer model rats
y measuring body weight, aberrant crypt foci formation, p16
ethylation, as well as expression of p16 and MUC2 proteins,
nd discussed molecular markers for CGMP intervention in rats
ith early colorectal cancer. The study revealed that CGMP
ight have certain prevention and therapeutic effects on the
ccurrence and development of early colorectal cancer.
.  Materials  and  methods
.1.  Animal  experiment
50 female SPF grade Wistar rats weighting 80–90 g from the
xperimental Animal Center of the Chinese People’s Libera-
ion Army Academy of Military Medical Sciences were used
n the experiments. The animal experimental protocols were
pproved with permit number of SYXK (Jin) 2012–2014 by
nstitutioanl Ethic Committee. The rats were fed convention-
lly. After accommodated to the environment for one week,
hey were randomly assigned into normal, model, as well as
hree CGMP (Tatua New Zealand) treatment groups with 10
ats in each group. Rats in all groups except normal group
ere intraperitoneally injected with dimethylhydrazine (DMH)
Sigma, USA) at 25 mg/kg w once a week [9,10]. Meanwhile,
ats in CGMP groups were intraperitoneally injected with 10, 50
r 100 mg/kg bw d of CGMP, respectively. Their diet, drinking
nd behavior were observed daily and their body weights were
ecorded weekly.
.2.  Detection  of  colon  aberrant  crypt  foci  (ACF)
Rat colon was taken from the incisions at the junction of
ecum and colon as well as pelvis, and cut open longitudinally.
fter removal of its content and rinsed with phosphate buffered
aline, the colon was spread between two layers of filter papers
nd placed in a glass container with 10% formalin for 24 h. The
xed sample was stained with 0.2% methylene blue solution
Fermentas) for 10–20 min and transferred onto a glass slide.
he number of ACF was counted with a microscope at 40×
agnification [11]. The pathological morphology includes (1)
ild or focal cell congestion, normal nuclear shape, no stratified
ell layers, no neoplastic cells, and normal mucus secretion; (2)
yperplasia, crypt opening expansion, volume increase, but no
uclear atypia; (3) diffused or focal atypical hyperplasia, nuclear
nlargement, congestion, increased nuclear layer, and reduced
ucus secretion.
.3.  Detection  of  p16  gene  methylation  in  rat  colonDNA purity was examined using a spectrophotometer (Bei-
ing Purkinje General Instrument Co., Ltd.). 20 L of extracted
NA was used to detect methylation using an EZ DNA
a
wan Wellness 2 (2013) 113–118
ethylation-Gold Kit (ZYMO Research Country) according to
he protocol provided by the manufacturer.
.4.  Methylation  speciﬁc  PCR  (MSP)
The methylation of p16 promoter were detected using methy-
ation primers 5′-AATTCGAGGAGAGCGATTCG-3′ and
′
-ACCTATATCGAAATACGACCGA-3′ to amplify a 155 bp
ragment and non-methylation primers 5′-ACCTATATCGA-
ATACGACCGA-3′ and 5′-GTGAATTTGAGGAGAGTGAT
TG-3′ to amplify a 156 bp fragment [12]. MSP was performed
n a 25 L system containing 0.2 mM PCR buffer, 0.2 mM dNTP,
0 pmol each primer and 30–50 ng DNA template. After the
eaction mixture was heated at 97 ◦C for 5 min and cooled down
n ice for 3 min, 2.5 units of Taq polymerase was added to ini-
iate the reaction under the following conditions: 40 cycles of
0 s at 94 ◦C, 30 s at 48 ◦C (M)/51 ◦C (U) and 30 s at 72 ◦C.
he products were detected by 2.5% agarose electrophoresis.
ppearance of methylation band was considered as methylation
hile appearance of only non-methylation band was considered
s non-methylation.
.5.  Detection  of  p16  and  MUC2  expression  in  rat  colon
ucosa
p16 and MUC2 expressions in rat colon mucosa were
etected using immunohistochemical methods and quantified
sing Image Pro-plus software by calculating its accumulated
mage optical density (IOD) value [13].
.6.  Statistical  analysis
All data was expressed as mean ±  standard deviation (x¯  ±  s)
nd analyzed using SPSS11.5 statistical software with variance
est. P  value of less than 0.05 was considered as statistical sig-
ificance.
.  Results
.1.  The  effects  of  CGMP  on  rat  general  status  and  body
eight
During the test, rats in all groups ate normally, showing no
ignificant differences. Rats in the model group showed obvious
hysical and mental abnormalities: their hair was scattered, and
heir eyes were dull and off-white. It can be seen from Table 1 that
ody weights of rats in all groups showed an increasing trend.
tatistical analysis of variance indicated that weekly changes
n body weights of rats in different groups were not signifi-
ant (P  > 0.05), i.e.  CGMP has no significant effect on the body
eights of rats with colon cancer.
.2.  Effect  of  CGMP  on  ACF  formation  in  rat  colonAbnormal enlargement of the midgut gland and the area
round it, increased staining intensity and crack-like openings
ere observed under light microscope at 40×  magnification.
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Table 1
Weight changes of rats in different groups.
Groups 1st week 3rd week 5th week 7th week 9th week 11th week 13th week 15th week
Normal control 80.5 ± 1.3 116.8. ± 1.9 150.3 ± 6.8 198.2 ± 6.2 220.0 ± 5.7 243.8. ± 3.3 270.8 ± 7.5 300.1 ± 2.3
Model control 85.3 ± 2.5 120.1 ± 9.2 158.4 ± 1.3 189.4 ± 9.5 210.7 ± 3.9 235.8 ± 1.9 260.1 ± 5.9 290.5 ± 3.1
Low CGMP dosage 82.1 ± 4.3 125.5 ± 7.9 160.7 ± 4.6 190.3 ± 4.3 213.4 ± 2.6 239.8 ± 5.4 265.7 ± 4.9 295.3 ± 8.7
M 188.
H 189.
T
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a
m
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g
F
Cedium CGMP dosage 84.5 ± 5.7 127.2 ± 4.3 165.2 ± 5.3 
igh CGMP dosage 89.1 ± 3.1 129.2 ± 5.7 175.6 ± 2.1 
able 2 shows the ACF number in colon of rats in all groups.
rom Table 2 and Fig. 1 it can be seen that there was no
CF in rats of the normal group. However, there were on aver-
ge 33.1 ±  3.1 ACF and 17.7 ±  5.7 large ACF in rats of the
odel group, indicating the successful establishment of DMH-
nduced colon cancer model. In addition, there were 27.8 ±  4.5,
A
t
i
ig. 1. The pathological slices of ACF in rats of each group. (A) normal control; (B)
GMP dosage.9 ± 3.1 208.5 ± 9.1 236.7 ± 3.5 264.3 ± 5.7 295.9 ± 3.0
5 ± 5.2 215.3 ± 4.7 242.3 ± 5.8 270.3 ± 4.1 305.3 ± 4.8
2.8 ±  5.4 and 20.6 ±  1.9 ACF and 13.2 ±  4.8, 14.1 ±  2.7 and
.7 ±  4.3 large ACF in rats of 10, 50 and 100 mg/kg bw d CGMP
roups, respectively. Although the number of ACF and large
CF in CGMP groups were significantly higher than that in
he normal group (P  < 0.01), they were much lower than that
n the model group. Rats in the 100 mg/kg bw d CGMP group
 model control; (C) low CGMP dosage; (D) medium CGMP dosage; (E) high
116 Q. Chen et al. / Food Science and Human Wellness 2 (2013) 113–118
Table 2
The change of ACF number in rats of each group.
Groups N ACF no./rat Large ACF no./rat
Normal control 10 0## 0##
Model control 10 33.1 ± 3.1** 17.7 ± 5.7**
Low CGMP dosage 10 27.8 ± 4.5** 13.2 ± 4.8**
Medium CGMP dosage 10 22.8 ± 5.4** 14.1 ± 2.7**
High CGMP dosage 10 20.6 ± 1.9**,# 8.7 ± 4.3*,#
* P < 0.05 compared to rats in normal group.
** P < 0.01 compared to rats in normal group.
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Fig. 3. The effect of CGMP on p16 expression of rats in different groups.
*P < 0.05 compared to normal control. **P  < 0.01 compared to normal con-
trol. +P < 0.05 compared to rats in model group. ++P < 0.05 compared to rats in
model group.
Fig. 4. The effects of CGMP on MUC2 expression of rats in different groups.
*
+
g
T
t
3
cP < 0.05 compared to ratsin model group.
## P < 0.01 compared to rats in model group.
howed statistical significance (P  < 0.05). The results suggested
hat CGMP could inhibit ACF formation. It showed the best
ffect in high dose group from the standpoint of the num-
er of ACF formation. But CGMP also showed significant
ffect in the middle dose group if other characters, including
pithelial thickening, methylation and formation of crack-like
penings/irregular shape/projections were taken into account. It
lso suggests that the effects of milk-derived CGMP on ACF
ontrolling is dose-dependent.
.3.  The  effect  of  CGMP  on  p16  gene  methylation  in  rat
ith colorectal  cancer
The purity test showed that the DNA extracts from colon
issues, containing intact colon genomic DNA, was not degraded
nd contaminated with protein and RNA. The ratio of absorption
t 260 and 280 nm was between 1.8 and 2.0, suggesting the high
urity of the obtained DNA.
The methylation specific primer pair could only amplify
he methylated fragment of p16 gene promoter, while the non-
ethylation primer pair could only amplify the non-methylated
16 gene promoter. The changes in the methylation of p16 gene
romoter in rats from different groups are shown in Fig. 2. Com-
ared with normal control group, the methylation of p16 gene
romoter in model group was significantly enhanced (P  < 0.05).
ig. 2. Relative methylation of p16 gene promoter of rats in different groups.
P < 0.05 compared to normal control. **P  < 0.01 compared to normal control;
P < 0.05 compared to rats in model group. ++P < 0.05 compared to rats in model
roup.
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oP < 0.05 compared to normal control. **P  < 0.01 compared to normal control.
P < 0.05 compared to rats in model group. ++P < 0.05 compared to rats in model
roup.
his enhancement was significantly attenuated by the adminis-
ration of 10, 50 or 100 mg/kg bw d CGMP (P  < 0.05).
.4.  Effect  of  CGMP  on  p16  and  MUC2  expression  in  rat
olon tissues
Immunohistochemical examination of p16 and MUC2
xpression indicated that rats the expression of p16 and MUC2
as significantly lower in the model group than the normal
roup (Figs. 3 and 4). However, it was attenuated by admin-
stration of 10, 50 or 100 mg/kg bw d CGMP, with the most
ignificant difference significance in the 100 mg/kg bw d CGMP
roup (P  < 0.05).
.  Discussion
The development of colorectal cancer is a complex patho-
ogical process which involves multiple steps and stages with
hanges from normal crypt foci to aberrant crypt foci, adenomas
ormation, expansion and eventual development to colorectal
ancer [14,15]. In recent years, the role of dietary factors in
he development of colorectal cancer is highly concerned.
ntake of food with high animal protein and fat content has
een found to positively correlate with the occurrence and
evelopment of colorectal cancer, while intake of large amounts
f vegetables and fruits would significantly inhibit this process
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16]. Moreover, studies on the bioactive peptides have become
ore and more active, with increasing numbers of biologi-
ally active peptides and their corresponding nutrients being
eparated. These peptides, such as anti-thrombosis peptides,
nti-tumor peptides, immunomodulation peptides, etc., can not
nly function as amino acid donors, but also have a wide range
f physiological functions roles [17,18,19].
In this study, the effects of CGMP on rats with DMH induced
olorectal cancer were analyzed. The results showed that CGMP
ould inhibit DMH-induced formation of ACF, which was pos-
tively related with the dosage of CGMP.
Existing evidences have shown that DNA methylation is due
o the methylation of cytidine residues in CpG dinucleotide by
ntracellular methyl transferase (Dnmt). This modification can
hange chromosome structures. Some functional food ingredi-
nts in human diet could alter protein expression by modifying
he methylation of their gene promoters, enhancers, silencers
nd insulators (non-coding region). p16 gene is one of the most
idely studied tumor suppressor gene in recent years. It is exten-
ively involved in the occurrence and development of varieties
f tumors, such as colorectal cancer, breast cancer and others.
erman et al. [20] first used methylation-specific PCR (MSP)
o detect changes of abnormal DNA methylation. Because of its
pecificity and sensitivity, this method has been widely accepted.
n addition, it was reported that, in colorectal cancer, the pos-
tive rate of p16 gene promoter methylation detected by MSP
as significantly higher than that using Southern blot method
nd restriction endonuclease method [21]. In this study, abnor-
al methylation of the p16 gene promoter was detected in rats
ith DMH-induced colorectal cancer using MSP and this abnor-
al methylation was reduced by administration of 10, 50 or
00 mg/kg bw d CGMP. Moreover, methylation of the p16 gene
romoter showed significant differences between untreated and
0 mg/kg bw d treated rats with DMH-induced colorectal can-
er. The results suggested that CGMP may change the activities
f enzymes involved in abnormal methylation, such as Dnmts.
The p16 gene encodes an inhibitory factor of cell cycle-
ependent kinase 4 (CKD4), one of the key regulators for G1
hase of the cell cycle. Thus, it could prevent cell division and
rowth, and regulate cell cycles. When there are deletion, muta-
ion or methylation on p16 gene, its encoded p16 protein is
nable to bind to CDK leading to increased binding between
yclin D and CDK4 and enhanced cell division and differentia-
ion. This will eventually result in the development of malignant
ancer. In contrast, enhanced p16 expression could inhibit the
rowth of cancer cells. Spillare et al. [22] found that p16 pro-
ein could inhibit the proliferation of colorectal cancer cells both
n vivo  and in  vitro.
Hanski et al. [23] found that expression of MUC2 protein was
ow in colorectal adenocarcinoma and it was further decreased
ith the reduction of metastatic potential of tumor cells. Cho
t al. [24] also showed that MUC2 expression was related with
ocal invasion and distant metastasis of colorectal cancer. In this
tudy, rats with DMH-induced colorectal cancer were intragas-
rically administrated with different doses of CGMP and the
xpression of p16 and MUC2 were examined using immuno-
hemistry. We found that the expression of p16 and MUC2 wasan Wellness 2 (2013) 113–118 117
nhanced in the model rats, which was significantly attenuated
y intragastrical administration of different doses of CGMP.
here was a significant difference between untreated model rats
nd 50 mg/kg bw d CGMP treated model rats, indicating that
GMP could enhance p16 and MUC2 protein expression in
olorectal cancer.
.  Conclusion
This study demonstrated that intragastrical administration of
00 mg/kg bw d CGMP could significantly reduce the number
f ACF in rats with DMH-induced colorectal cancer, indicating
hat CGMP plays certain preventive roles in colorectal car-
inogenesis. From the epigenetics point of view, intragastrical
dministration of 50 mg/kg bw d CGMP could effectively inhibit
berrant methylation of p16 gene promoter in rats with DMH-
nduced colorectal cancer and enhance the expression of p16 and
UC2 in intestinal mucosa in rats with DMH-induced colorec-
al cancer, prompting that administration of bioactive peptide
GMP is a feasible way for the control and prevention of early
olorectal cancer. The study also showed that the dose of CGMP
esulting in physiological changes in epithelium observed dur-
ng the development process using routine pathological sections
as different from that resulting in epigenetic alteration. Thus,
nalysis of the expression of genes related to colorectal cancer
s of important values for early warning of colorectal cancer.
owever, further researches are needed to clarify the molecular
echanisms and pathways by which CGMP could enhance the
xpression of genes related to colorectal cancer.
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